STOCKHOLM, Sweden, Feb. 21, 2026 — Johnson & Johnson announced new long-term findings from the QUASAR long-term extension study demonstrating that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic remission through Week 140 in adults with moderately to severely active ulcerative colitis (UC). Presented at the European Crohn’s and Colitis Organisation (ECCO) 2026 congress, the data highlight durable disease control, high remission rates, and sustained intestinal healing across multi-year treatment.
Science Significance
The QUASAR long-term extension results reinforce the growing scientific validation of IL-23–targeted biologic therapy in inflammatory bowel disease. At Week 140, 80.8% of treated patients achieved clinical remission, while 53.6% reached endoscopic remission — a key indicator of mucosal healing. Notably, 78.6% achieved histo-endoscopic mucosal improvement, demonstrating healing at both tissue and visual levels. Sustained remission durability was further confirmed as 87.5% of patients in remission at Week 44 maintained remission through Week 140. TREMFYA® operates as a dual-acting monoclonal antibody, blocking IL-23 while binding CD64 receptors on cytokine-producing immune cells, thereby neutralizing inflammatory signaling at its cellular source. This mechanistic approach advances precision immunology by targeting both cytokine pathways and upstream immune activation processes driving chronic intestinal inflammation.
Regulatory Significance
From a regulatory perspective, long-term extension data such as QUASAR play a critical role in supporting label expansions, lifecycle management strategies, and post-marketing safety surveillance. TREMFYA® already holds approvals from both the U.S. FDA and European Commission for ulcerative colitis and Crohn’s disease across subcutaneous and intravenous induction regimens. Sustained multi-year remission and absence of new safety concerns strengthen the therapy’s long-term benefit-risk profile. Regulatory agencies rely on such durability datasets to evaluate continued therapeutic value, steroid-sparing outcomes, and real-world disease modification potential, particularly for chronic immune-mediated diseases requiring lifelong management.
Business Significance
Advertisement
Commercially, the long-term outcomes reinforce Johnson & Johnson’s strategic leadership in the immunology and gastroenterology biologics market. Durable remission data support competitive differentiation in an increasingly crowded IL-23 and IBD therapeutic landscape. High retention rates — with nearly 89% of eligible participants completing treatment through Week 140 — reflect strong tolerability and adherence, key drivers of market uptake. Sustained corticosteroid-free remission further enhances pharmacoeconomic value by reducing hospitalization, surgery, and steroid-related complications. Long-term efficacy also supports formulary inclusion and reimbursement expansion across global healthcare systems.
Patients’ Significance
For patients living with ulcerative colitis, the findings represent a major advancement in long-term disease management. UC is a lifelong inflammatory disorder associated with debilitating symptoms, frequent flare-ups, and elevated colorectal cancer risk. Achieving deep remission — including mucosal and histologic healing — is linked to fewer relapses, reduced steroid dependence, and lower surgical intervention rates. The sustained remission observed through nearly three years provides reassurance regarding treatment durability. Importantly, efficacy was maintained regardless of prior biologic or JAK inhibitor exposure, expanding therapeutic relevance to treatment-experienced populations.
Policy Significance
Healthcare policymakers increasingly prioritize therapies demonstrating long-term disease modification rather than short-term symptom control. Durable remission data support value-based care frameworks by reducing cumulative healthcare costs associated with hospitalizations, surgeries, and productivity loss. As inflammatory bowel disease prevalence rises globally, biologics capable of maintaining multi-year remission align with policy objectives focused on chronic disease burden reduction. The QUASAR findings may inform treatment guidelines, reimbursement models, and immunology care pathways.
The QUASAR long-term extension study positions TREMFYA® as a durable, dual-acting IL-23 biologic capable of sustaining deep remission in ulcerative colitis through three years. With strong clinical, endoscopic, and histologic outcomes alongside consistent safety, the therapy continues to shape the evolving standard of care in inflammatory bowel disease, reinforcing the long-term value of targeted immunologic intervention.
Source: Johnson & Johnson press release
